Table 2 Quality of life in ENVISION trial participants at baseline
From: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
Assessment, Mean (SD) | Placebo (n = 46) | Givosiran (n = 48) |
|---|---|---|
SF-12 PCS | 38.1 (9.8) | 39.5 (9.8) |
SF-12 MCS | 41.8 (10.3) | 39.9 (8.3) |
EQ VAS | 64.3 (19.6) | 62.6 (22.6) |
Employed in past 4Â weeks, n | 21 | 20 |
  Days of work missed in past 4 weeks | 6.1 (6.5) | 3.3 (3.5) |
Hours of caregiver support in past week | 11.3 (28.1) | 12.5 (32.3) |